QUADRAMET Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Quadramet, and what generic alternatives are available?
Quadramet is a drug marketed by Lantheus Medical and is included in one NDA.
The generic ingredient in QUADRAMET is samarium sm-153 lexidronam pentasodium. Additional details are available on the samarium sm-153 lexidronam pentasodium profile page.
Summary for QUADRAMET
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 8 |
| Clinical Trials: | 3 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for QUADRAMET |
| What excipients (inactive ingredients) are in QUADRAMET? | QUADRAMET excipients list |
| DailyMed Link: | QUADRAMET at DailyMed |
Recent Clinical Trials for QUADRAMET
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Mayo Clinic | Phase 1/Phase 2 |
| National Cancer Institute (NCI) | Phase 1/Phase 2 |
| Sidney Kimmel Cancer Center at Thomas Jefferson University | Phase 1 |
US Patents and Regulatory Information for QUADRAMET
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lantheus Medical | QUADRAMET | samarium sm-153 lexidronam pentasodium | INJECTABLE;INJECTION | 020570-001 | Mar 28, 1997 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for QUADRAMET
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Lantheus Medical | QUADRAMET | samarium sm-153 lexidronam pentasodium | INJECTABLE;INJECTION | 020570-001 | Mar 28, 1997 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for QUADRAMET
See the table below for patents covering QUADRAMET around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| European Patent Office | 0408701 | COMPLEXES D'ACIDES AMINOPHOSPHONIQUES MACROCYCLIQUES DE TRAITEMENT DE TUMEURS CALCIFIANTES. (MACROCYCLIC AMINOPHOSPHONIC ACID COMPLEXES, THEIR PREPARATION, FORMULATIONS AND USE.) | ⤷ Try a Trial |
| Poland | 166453 | ⤷ Try a Trial | |
| Czech Republic | 290556 | Způsob čiątění kyseliny ethylendiamintetra(methylenfosfonové) nebo kyseliny 1,4,7,10-tetraazacyklododekan-1,4,7,10-tetra(methylenfosfonové) (Purification process of ethylenediaminetetra(methylenephosphonic) acid or 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra(methylenephosphonic)acid) | ⤷ Try a Trial |
| China | 1031191 | ⤷ Try a Trial | |
| World Intellectual Property Organization (WIPO) | 9006776 | ⤷ Try a Trial | |
| New Zealand | 231818 | COMPLEXES COMPRISING A MACROCYCLIC AMINOPHOSPHONIC ACID AND A RADIONUCLIDE SELECTED FROM SM, GD, HO, LU, Y AND YB | ⤷ Try a Trial |
| Australia | 639899 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for QUADRAMET
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0164843 | SPC/GB98/028 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: 153 SAMARIUM ETHYLENEDIAMINETETRAMETHYLENEPHOSPHONIC ACID (QUADRAMET); REGISTERED: CH CH 54265 19971006; UK EU/1/97/057/001 19980205 |
| 0164843 | C980021 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: SAMARIUM[153 SM] LEXIDRONAM, DESGEWENST IN DE VORM VAN EEN FYSI OLOGISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET PENTANATRIUMZO UT; NAT.REGISTRATION NO/DATE: C(1998)253 DEF 19980205; FIRST REGISRATION: EU/1/97/057/001 19980205 |
| 0513917 | 98C0018 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: SAMARIUM LEXIDRONAM PENTASODIQUE; NAT. REGISTRATION NO/DATE: EU/1/97/057/001 19980205; FIRST REGISTRATION: CH - 54265 19971006 |
| 0164843 | 98C0023 | Belgium | ⤷ Try a Trial | PRODUCT NAME: SAMARIUM (153 SM) LEXIDRONAM PENTASODIQUE; NAT. REGISTRATION NO/DATE: EU/1/97/057/001 19980205; FIRST REGISTRATION: CH 54265 19971006 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
